Multiple Sclerosis Enrollment Form



Fax Referral To: 1-888-280-1191 OR 787-759-4161

Phone: 1-888-280-1190 OR 787-759-4162

Email Referral To: Customer.ServiceFax@CVSHealth.com

Address: 280 Avenida Jesus T. Pinero Ste B Rio Piedras, PR 00927 Six Simple Steps to Submitting a Referral

| PATIENT | INFORMATION | (Complete or include demographic sheet) | |
|------------------------|---------------------------|--|--|
| | | | Gender: 🗌 Male 🔲 Female |
| | | City, State, 2 | |
| Preferred Conf | tact Methods: 🗌 Phon | e (to primary # provided below) 🗌 Text (to cell # pr | ovided below) 🗌 Email (to email provided below) |
| Note: Carrier cha | arges may apply. If unabl | e to contact via text or email, Specialty Pharmacy wil | l attempt to contact by phone. |
| Primary Phone | e: | Alternate F | Phone: |
| | | | Primary Language: |
| f Minor , Parer | nt/Caregiver/Guardiar | Name (Last, First): Relat | ionship to minor: |
| PRESCRIE | BER INFORMATIO | N | |
| | | | se #: |
| NPI #· | DFA #· | Group or Hospital: | 50 m. |
| Address | DLA # | City State 7IP Code | z· |
| Phono: | Eav | Contact Porson: | e: Contact's Phone: |
| -11011e | Fax | Contact Ferson | Contact's Priorie. |
| = | | | |
| <u> 3</u> INSURAN | ICE INFORMATIO | $oldsymbol{N}$ Please fax copy of prescription and insurance car | ds with this form, if available (front and back) |
| | | | |
| DIAGNOS | SIS AND CLINICAL | INFORMATION | |
| | | | sian Cuita C Othan |
| | | Patient Office Coram Ambulatory Infus | |
| infusion Sit | e: Name: | Address: | |
| | > | (Please include street | address, suite #, city, state, ZIP) |
| <u> Diagnosis (ICI</u> | | | |
| G35 Multip | le Sclerosis (MS) | Other Code: Descripti | ion |
| | _ | | |
| f MS, please | Primary progr | essive MS (PPMS) | |
| ndicate type: | Relapsing-ren | nitting MS (RRMS) | |
| | Progressive-r | elapsing MS (PRMS) | |
| | Secondary pro | ogressive MS (SPMS); If SPMS, does the patier | nt have documented relapses? Yes No |
| | First clinical e | oisode of MS; If so, does the patient have MRI f | features consistent with MS? Yes No |
| Height: ir | | • | rgies: |
| · | | res No No Not applicable (e.g., male, post-r | |
| , | , | | |
| For Gilenva: P | Please provide the pation | ent's QTc interval:ms 🔲 Unknown | |
| | | rapy with Gilenya? Yes No | |
| 3 the patient o | dirently receiving the | apy with diterrya: res No | |
| Me drug(s) po | ot able to use: | | |
| | | usto recognice trial duration | |
| Drug: | | uate response, trial duration | |
| | | ance, specify: | |
| | | indication, specify: | |
| Drug: | | uate response, trial duration | |
| | ∐ Intolera | ance, specify: | |
| | ☐ Contra | indication, specify: | |
| Nursing: | | | |
| Specialty phar | macy to coordinate in | jection training/ home health infusion nurse vis | sit necessary 🗌 Yes 🔲 No |
| | | on Clinic 🔲 Outpatient Health 🗌 Home Health | |
| | ng not necessary. Date | | |
| | | nt Pt already independent Referred by N | MD to alternate trainer |

Multiple Sclerosis Enrollment Form Medications A-D

(Aubagio, Avonex, Bafiertam, Betaseron, Briumvi, Copaxone, Dalfampridine, Dimethyl Fumarate)

| D. C. L.N. | | omplete Patient and Prescriber Information | |
|---|---|---|---|
| Patient Name: Prescriber Name: | | Patient DOB: Prescriber Phone: | |
| 5 PRESCRIPTION INFO | | Trescriber Friorie. | |
| MEDICATION | STRENGTH | DOSE & DIRECTIONS | QUANTITY/REFILLS |
| ☐ Aubagio | ☐ 7 mg ☐ 14 mg | Take one tablet by mouth once a day. | 30-day supply (1 bottle) 90-day supply (3 bottles) Refills: |
| Avonex | 30 mcg prefilled syringe 30 mcg pen (single doses) | Inject 30 mcg intramuscularly once a week | 28-day supply (1 box) 84-day supply (3 kits) Refills: |
| Bafiertam | 95 mg capsule | Take one 95 mg capsule by mouth twice a day for 7 days. Starting on Day 8, take 190 mg (two 95 mg capsules) twice a day by mouth Other: | 30-day supply 90-day supply Other: Refills: |
| Betaseron | 0.3 mg | ☐ Inject 0.25 mg (1mL) SC every other day. ☐ Dose Titration: • Weeks 1-2: Inject 0.0625 mg/0.25 mL SC QOD; • Weeks 3-4: Inject 0.125 mg/0.50 mL SC QOD; • Weeks 5-6: Inject 0.1875 mg/0.75 mL SC QOD; • Weeks 7+: Inject 0.25 mg/1 mL SC QOD ☐ Other | 28-day supply (1 kit of 14 vials) 84-day supply (3 kits of 14 vials) Refills: |
| ☐ Betaject Lite Autoinjector | N/A | Betaject Lite can be ordered through Betaplus #1-800-788-1467 | Quantity: 0 Refills: 0 |
| ☐ Briumvi | 150 mg/6 mL vial | Briumvi must be diluted with 0.9% Sodium Chloride Injection 250 mL First Infusion: Administer 150 mg (1 vial) IV over 4 hours Second Infusion: Administer 450 mg (3 vials) IV over 1 hour two weeks after the first infusion Subsequent Infusions: Administer 450 mg (3 vials) IV over 1 hour 24 weeks after the first infusion and every 24 weeks thereafter. Please use the following toll-free fax/phone numbers for Briumvi enrollments. Fax: 1-855-592-6890; Phone: 1-866-526-4984 | 1 vials 3 vials Other: |
| Copaxone | 20 mg prefilled syringe | Inject 20 mg SC daily. | 30-day supply (1 kit) 90-day supply (3 kits) Refills: |
| ☐ Copaxone | 40 mg prefilled syringe | Inject 40 mg SC three times a week. | 28-day supply (12 syringes) 84-day supply (36 syringes) Refills: |
| Autoject 2 for glass syringe injection device | N/A | Autoject 2 can be ordered through Shared Solutions #1-800-887-8100 | Quantity: 0 Refills: 0 |
| ☐ Dalfampridine | 10 mg extended release tablet | Take one tablet (10 mg) twice daily (approximately 12 hours apart) | 30-day supply 90-day supply Refills: |
| ☐ Dimethyl Fumarate | Starter Pack (14 capsules of 120 mg & 46 capsules of 240 mg) | Take one 120 mg capsule by mouth twice a day for 7 days, followed by one 240 mg capsule by mouth twice a day. | Quantity: 30-day supply Refills: |
| ☐ Dimethyl Fumarate | 120 mg capsule | Administer 120 mg twice a day orally for seven days. Other | Quantity: 7-day supply Refills: |
| ☐ Dimethyl Fumarate | 120 mg capsule | ☐ Other | 30-day supply 60-day supply Other: Refills: |
| ☐ Dimethyl Fumarate | 240 mg capsule | Administer 240 mg twice a day orally after day seven Other | 30-day supply 90-day supply Refills: |

Multiple Sclerosis Enrollment Form Medications E-L

(Extavia, Fingolimod, Gilenya, Glatiramer Acetate, Glatopa, Kesimpta, Lemtrada)

| Patient Name: | | ase Complete Patient and Prescriber Information Patient DOB: | | | |
|---|--|---|--|--|--|
| Prescriber Name: | | | Prescriber Phone: | | |
| PRESCRIPTION INFORMATION | | | | | |
| MEDICATION | STRENGTH | DOSE & DIRECTIONS | QUANTITY/REFILLS | | |
| ☐ Extavia ☐ Extavia Auto-Injector II | 0.3 mg | ☐ Inject 0.25 mg (1 mL) SC every other day. ☐ Dose Titration: • Weeks 1-2: Inject 0.0625 mg/0.25 mL SC QOD • Weeks 3-4: Inject 0.125 mg/0.50 mL SC QOD • Weeks 5-6: Inject 0.1875 mg/0.75 mL SC QOD • Weeks 7+: Inject 0.25 mg/1 mL SC QOD ☐ Other | 30-day supply (1 kit) 90-day supply (3 kits) Refills: | | |
| Fingolimod | 0.5 mg | Take one capsule by mouth daily | 30-day supply (1 bottle) 90-day supply (3 bottles) Refills: | | |
| Gilenya | 0.5 mg | Take one capsule by mouth daily | 30-day supply (1 bottle) 90-day supply (3 bottles) Refills: | | |
| Glatiramer Acetate | 40 mg prefilled syringe | Inject 40 mg SC three times a week | 28-day supply (12 syringes) 84-day supply (36 syringes) Refills: | | |
| WhisperJECT Autoinjector device (1st fill only) | N/A | Use as directed | Quantity:1 Refills: 0 | | |
| ☐ Welcome Kit (1st fill only) | N/A | Use as directed | Quantity:1 Refills: 0 | | |
| Glatopa | 20 mg prefilled syringe | Inject 20 mg SC daily | 30-day supply (1 kit) 90-day supply (3 kits) Refills: | | |
| ☐ Kesimpta | 20 mg/0.4 mL single-dose prefilled Sensoready pen | Loading Dose: Administer 20 mg subcutaneously at Week 0, 1, and 2 Maintenance Dose: Administer 20 mg subcutaneously once a month starting Week 4 | 28-day supply 84-day supply Other: Refills: | | |
| Lemtrada | N/A | Please complete an MS One to One/Lemtrada enrollment form and indicate CVS Specialty as your preferred pharmacy provider. (For questions, please contact MS One to One at 1-855-676-6326). | Quantity: 0 Refills: 0 | | |

Multiple Sclerosis Enrollment Form Medications M

(Mavenclad)

| | | Р | lease Complete Patient and Prescr | iber Information | | |
|--------------------|----------------------|--------------------|---|--------------------------|--|--|
| Patient Name: | | | | ÷ | | |
| Prescriber Name: | | Prescriber Phone: | | | | |
| 5 PRESCRIPT | TION INF | FORMA [*] | ΓΙΟΝ | | | |
| MEDICATION | STREN | GTH | DOSE & DIRECTIO | NS | QUANTITY/REFILLS | |
| ☐ Mavenclad 10 mg | | | Please see below for Week 1 and Week 5 dosing chart Patient Weight:kg orlb Treatment Course: Year 1 Year 2 | | Week 1: 4-pack; Quantity: 5-pack: Quantity: 6-pack; Quantity: 7-pack; Quantity 8-pack; Quantity 9-pack; Quantity 10-pack; Quantity Week 5: 4-pack; Quantity: 5-pack: Quantity: 6-pack; Quantity: 7-pack; Quantity: 8-pack; Quantity 9-pack; Quantity 8-pack; Quantity 8-pack; Quantity 9-pack; Quantity 10-pack; Quantity Refills: 0 | |
| | | | mg tablets per week | | | |
| Weight Range | Do | ose in mg (N | umber of 10 mg Tablets) per Cycle | | Construction of the Constr | |
| kg | | | <u> </u> | First Cycle Second Cycle | | |
| 40 to less than 50 | | | 40 mg (4 tablets) 40 mg (4 tablets) | | , | |
| 50 to less than 60 | | 50 mg (5 tablets) | 50 mg (5 tablets) | | | |
| 60 to less than 70 | | | 60 mg (6 tablets) | 60 mg (6 tablets) | | |
| 70 to less than 80 | | | 70 mg (7 tablets) | | 70 mg (7 tablets) 70 mg (7 tablets) | |
| 80 to less than 90 | | 80 mg (8 tablets) | | | <u> </u> | |
| | | | 90 mg (9 tablets) 80 mg (8 tablets) 90 mg (9 tablets) 90 mg (9 tablets) | | 90 mg (9 tablets) | |
| 110 and above | 100 to less than 110 | | 100 mg (10 tablets) | 100 mg (10 tablets) | | |
| | | | ioo ing (io tabloto) | <u>'</u> | oo mg (ro tabloto) | |

Multiple Sclerosis Enrollment Form Medications M-P

(Mayzent, Ocrevus, Plegridy, Ponvory)

| Patient Name: | | omplete Patient and Prescriber Information Patient DOR: | |
|---|---|--|--|
| Prescriber Name: | | Patient DOB: Prescriber Phone: | |
| _ | ION INFORMATION | | |
| MEDICATION | STRENGTH | DOSE & DIRECTIONS | QUANTITY/REFILLS |
| Mayzent Starter Pack (for 1 mg maintenance dose patients) | 0.25 mg tablet | Day 1: take 1 x 0.25 mg tablet by mouth once a day; Day 2: take 1 x 0.25 mg tablet by mouth once a day; Day 3: take 2 x 0.25 mg tablets by mouth once a day; Day 4: take 3 X 0.25 mg tablets once a day Other: | Quantity: 4-day supply Refill: 0 |
| Mayzent Starter Pack (for 2 mg maintenance dose patients) | 0.25 mg tablet | Day 1: take 1 x 0.25 mg tablet by mouth once a day; Day 2: take 1 x 0.25 mg tablet by mouth once a day; Day 3: take 2 x 0.25 mg tablets by mouth once a day; Day 4: take 3 X 0.25 mg tablets once a day; Day 5: take 5 X 0.25 mg tablets once a day. Other: | Quantity: 5-day supply Refill: 0 |
| Mayzent (maintenance prescription) | 1 mg tablet 2 mg tablet | Administer one tablet by mouth once a day. | 30-day supply 90-day supply Refills: |
| Ocrevus | 300 mg/10 mL (30 mg/mL) single dose vial | ☐ Induction: Infuse 300 mg IV over approximately 2.5 hours. Follow with a second 300 mg IV infusion over approximately 2.5 hours two weeks later. Infusions may be interrupted or slowed as needed. ☐ Maintenance: Infuse 600 mg IV over approximately 2 to 3.5 hours every 6 months. Infusions may be interrupted or slowed as needed. Please use the following toll-free fax/phone numbers for Ocrevus enrollments. Fax: 1-855-592-6890; Phone: 1-866-526-4984 | 2 vials Other: Refills: |
| Plegridy | Pen Starter Pack (one 63 mcg pen & one 94 mcg pen) Pre-Filled Syringe Starter Pack (one 63 mcg pre-filled syringe & one 94 mcg pre- filled syringe) | Administer 63 mcg/0.5 mL SC on Day 1 followed by 94 mcg/0.5 mL SC on Day 15 Administer 63 mcg/0.5 mL IM on Day 1 followed by 94 mcg/0.5 mL IM on Day 15 | Quantity: 28-day supply Refills: |
| ☐ Plegridy | Pen Maintenance Pack (two 125 mcg pens) for SC administration Pre-Filled Syringe Maintenance Pack (two 125 mcg pre-filled syringes) for SC administration Pre-Filled Syringe Maintenance Pack (two 125 mcg pre-filled syringes) for IM administration | Administer 125 mcg/0.5 mL SC every 14 days Administer 125 mcg/0.5 mL IM every 14 days. Other | 28-day supply (1 pk) 84-day supply (3 pks) Refills: |
| Ponvory | Starter Pack | Titration: Day 1-2: Take 2 mg tablet by mouth once daily Day 3-4: Take 3 mg tablet by mouth once daily Day 5-6: Take 4 mg tablet by mouth once daily Day 7: Take 5 mg tablet by mouth once daily Day 8: Take 6 mg tablet by mouth once daily Day 9: Take 7 mg tablet by mouth once daily Day 10: Take 8 mg tablet by mouth once daily Day 11: Take 9 mg tablet by mouth once daily Day 12-14: Take 10 mg tablet by mouth once daily | Quantity: 14-day starter pack Refills: |
| Ponvory | 20 mg tablets | Maintenance Dose Day 15 and thereafter: Take 20 mg tablet by mouth once daily | 30-day supply (30 tablets) 90-day supply (90 tablets) Refills: |

Multiple Sclerosis Enrollment Form Medications R-Z

(Rebif, Ribiject II, Tecfidera, Tysabri, VUMERITY, Zeposia)

| | Please Com | plete Patient and Prescriber information | |
|-------------------|---|--|---|
| Patient Name: | | Patient DOB: | |
| Prescriber Name | : | Prescriber Phone: | |
| 5 PRESCRIP | TION INFORMATION | | |
| MEDICATION | STRENGTH | DOSE & DIRECTIONS | QUANTITY/REFILLS |
| Rebif | ☐ Titration Pack (six 8.8 mcg & six 22 mcg prefilled syringes) ☐ Rebidose Titration Pack (six 8.8 mcg prefilled autoinjectors & six 22 mcg prefilled autoinjectors) | Weeks 1-2: Inject 8.8 mcg SC three times a week Weeks 3-4: Inject 22 mcg SC three times a week | Quantity: 28-day supply (1 kit) Refills: |
| Rebif Rebiject II | 22 mcg prefilled syringe 44 mcg prefilled syringe Rebidose 22 mcg prefilled autoinjector Rebidose 44 mcg prefilled autoinjector | ☐ Inject 44 mcg SC three times a week. ☐ Other | 28-day supply (1 kit) 84-day supply (3 kits) Refills: |
| ☐ Tecfidera | Titration Starter Pack (14 capsules of 120 mg & 46 capsules of 240 mg) | Take one 120 mg capsule by mouth twice a day for 7 days, followed by one 240 mg capsule by mouth twice a day. | Quantity: 30-day supply Refills: |
| Tecfidera | 120 mg capsules 240 mg capsules | ☐ Take 240 mg by mouth twice a day. ☐ Other | 7-day supply 30-day supply 90-day supply Refills: |
| ☐ Tysabri | NA | Please complete an MS Touch/Tysabri enrollment form and indicate CVS Specialty as your preferred pharmacy. (For questions, please contact TOUCH Prescribing Program at 1-800-456-2255). | Quantity: 0 Refill: 0 |
| ☐ VUMERITY | 231 mg capsule | ☐ Take one 231 mg capsule twice a day by mouth for 7 days. Starting on Day 8, take 462 mg (two 231 mg capsules) twice a day by mouth. ☐ Other | 30-day supply 90-day supply Refills: |
| ☐ Zeposia | Starter Kit (4 capsules of 0.23 mg, 3 capsules of 0.46 mg and one bottle containing 30 capsules of 0.92 mg) | Take 0.23 mg capsule once daily on days 1-4, followed by 0.46 mg capsule once daily on days 5-7, then take 0.92 mg capsule once daily starting on day 8) | Quantity: 37-day supply Refill: 0 |
| ☐ Zeposia | 7-Day Starter Pack (4 capsules of 0.23 mg and 3 capsules of 0.46 mg) | Take 0.23 mg capsule once daily on days 1-4, followed by 0.46 mg capsule once daily on days 5-7 | Quantity: 7-day supply Refill: 0 |
| Zeposia | 0.92 mg capsules | Take 0.92 mg capsule once daily | 30-day supply 90-day supply Refills: |

Multiple Sclerosis Enrollment Form Nursing Medications

| <u> </u> | | | | |
|--|-------------------|--|--|--|
| Please Complete Patient and Prescriber information | | | | |
| Patient Name: | Patient DOB: | | | |
| Prescriber Name: | Prescriber Phone: | | | |
| PRESCRIPTION INFORMATION | | | | |

Complete Items below, required for Home Infusion/Coram AIS:

| MEDICATION/SUPPLIES | ROUTE | DOSE/STRENGTH/DIRECTIONS | QUANTITY/REFILLS |
|--|--------------|---|------------------------------------|
| Catheter PIV PORT PICC | IV | Catheter Care/Flush – Only on drug admin days – SASH or PRN to maintain IV access and patency PIV – NS 5 mL (Heparin 10 units/mL 3-5mL if multiple days) PORT/PICC – NS 10 mL & Heparin 100units/mL 3-5 mL, and/or 10 mL sterile saline to access port a cath | Quantity: Refills: |
| Epinephrine **nursing requires** | □ IM □ sc | Adult 1:1000, 0.3 mL (>30 kg/>66 lbs) Peds 1:2000, 0.3 mL (15-30 kg/33-66 lbs) Infant 0.1 mL/0.1 mL, 0.1mL (7.5-15 kg/16.5-33 lbs) PRN severe allergic reaction – Call 911 May repeat in 5-15 minutes as needed | Quantity: Refills: |
| Patient is interested in patient support pro | ograms | STAMP SIGNATURE NOT ALLOWED Ancillary supplies and kits prov | rided as needed for administration |
| | | | |

5 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

| "Dispense As Written" / Brand Medically Necessary / Do Not DAW / May Not Substitute Prescriber's Signature: | Substitute / No Substitution / Date: | May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature: | Date: |
|---|--------------------------------------|--|---|
| CA, MA, NC & PR: Interchange is mandated unless Prescriber w | rites the words "No Substitution" | ATTN: New York and Iowa provide | rs, please submit electronic prescription |

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. or one of its affiliates

©2023 CVS Pharmacy, Inc. or one of its affiliates. 75-40946A 01/04/23

Page 7 of 7